Laurus Labs Q3 FY26 Earnings Call Transcript Released
Laurus Labs Q3 FY26 earnings call transcript released on January 23, 2026. Revenues stood at ₹1,778 crore with EBITDA margins over 27%. Significant CAPEX in peptide and ADC/gene therapy labs. Generics grew 37% to ₹1,327 crore. 9-month revenue reached ₹5,001 crore.
The release of a detailed earnings call transcript provides significant information to investors and analysts about the company's performance, strategy, and future outlook. This allows for informed investment decisions, thus having a medium impact.
The announcement is a transcript of a conference call, providing detailed financial and operational updates. While the company reported strong performance, the sentiment is neutral as it primarily reports factual information and management discussions without a significant positive or negative event.
Laurus Labs Limited has released the transcript of its Q3 FY26 earnings conference call, which was hosted on January 23, 2026. The call featured management, including Founder & CEO Dr. Satyanarayana Chava, Executive Directors, and AVP of Investor Relations Mr. Vivek Kumar, along with moderator Mr. Nitin Agarwal from DAM Capital Advisors Limited.
During the call, the management highlighted strong operational and financial performance for the quarter. Revenues for Q3 FY26 stood at ₹1,778 crore, with gross margins expanding to around 60% and EBITDA margins reaching over 27%. The company achieved these results through strong performance in its generics business and clinical and commercial supplies for CDMO programs.
Key updates included significant CAPEX investments in peptide development and manufacturing infrastructure. The company also operationalized its antibody-drug conjugate (ADC) and gene therapy process development labs in Hyderabad, with GMP manufacturing facility construction on track. The joint investment in Krka Pharma was also mentioned, aligning with plans to support ongoing FDA facility construction in Hyderabad, with Phase-1 expected by mid-2027.
In the CDMO segment, cumulative 9-month performance showed over 50% growth, driven by recurring business from long-term customers. Q3 small molecule sales were ₹408 crore, in line with expectations due to complex synthetic processes. The Bio division reported Q3 sales of ₹43 crore, with plans for a Phase-1 capacity of over 400 kiloliters for the commercial-scale fermentation facility at Vizag to be operational by the end of 2026.
The generics division reported revenues of ₹1,327 crore for Q3, a 37% growth, supported by higher ARV volumes and strong offtake of recently launched products in developed markets. The oral solid facility expansion is progressing well, with a significant part of the plant capacity becoming operational during the quarter.
On the R&D front, overall R&D spend was 4.1% of sales for the 9 months of FY26. The company also reported successfully passing close to 110 quality audits without critical points during the nine months. In ESG, Laurus Labs received an 81 out of 100 score from S&P Global.
Financial highlights for the 9 months of FY26 included total income from operations of approximately ₹5,001 crore, a 30% growth. EBITDA stood at ₹1,303 crore with a margin of 26.1%. Profit after tax for the 9 months was ₹610 crore, a growth of 388%. ROCE improved to 18.5%. CAPEX for the quarter was ₹246 crore, and cumulatively ₹735 crore for the 9 months. Net debt stood at ₹2,092 crore, with debt to EBITDA decreasing to around 1.2x.
Discussions during the Q&A included CAPEX plans for FY27 (estimated to be over ₹1,000 crore), investments in peptides and ADCs, and the sustainability of gross margins around 60%. The company also clarified its strategy to not enter large-scale MAB manufacturing or sterile manufacturing, focusing instead on existing growth plans.
What to do with a filing like this
Laurus Labs Limited filed this with the NSE as a statutory disclosure, categorised under concall scheduled. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Laurus Labs Limited. Read the original for the full detail.